RxDoctor Payments Data

Todd Brittain, DO

Ophthalmology · Hermantown, MNNPI 1073876397

Payments from drug & device makers

$288in general payments, 2019–2025

Across 13 payments — averaging $22.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$83
  • Rxsight Inc$71
  • Glaukos Corporation$29
  • Sight Sciences, Inc.$26
  • Ocular Therapeutix, Inc.$23
  • The Cameron-ehlen Group, Inc.$20
  • plus $36 from 2 others

What the payments were for

  • Food & beverage$288100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Alcon4$83
Rxsight Inc3$71
Glaukos Corporation1$29
Sight Sciences, Inc.1$26
Ocular Therapeutix, Inc.1$23
The Cameron-ehlen Group, Inc.1$20
Biotissue Holdings Inc.1$19
Novartis1$17

How this compares

$288 in reported general payments places this provider in the 45th percentile of 330 ophthalmology providers in Minnesota.

See all ophthalmology providers in Minnesota

Medicare billing

Part B allowed, 2024
$147,798
Medicare patients
422
Services billed
1,368

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost33$22,523
RestasisCyclosporine13$19,209
Latanoprost410$8,481
Prednisolone Acetate145$7,119
Brimonidine Tartrate80$5,524
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol18$4,978
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat150$3,740
Ketorolac Tromethamine127$3,493
SimbrinzaBrinzolamide/Brimonidine Tart12$3,248
Timolol Maleate184$2,705
Cosopt PfDorzolamide/Timolol/Pf11$2,310
Ofloxacin117$1,498
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha59$622
ValacyclovirValacyclovir Hcl19$617
Dorzolamide Hcl22$597

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AlconSimbrinza$83$3,24812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 330 ophthalmology providers in Minnesota.

Other ophthalmology in Hermantown

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →